Surface Logix, a Brighton, MA-based developer of drugs for obesity and diabetes, pulled in $4 million in an offering of equity, options, and warrants that could total $4.6 million, according to an SEC filing. The startup, which launched in 2001 with technology from Harvard chemist George Whitesides, raised $20 million in Series E funding last year, with backing from Arch Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development, Unilever Technology Ventures, and Venrock Associates.The filing for the newest funding for Surface lists 17 investors.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
